CDK4/6 Inhibitors Are Tested in Adjuvant Setting
Although ET significantly reduces the risk of HRpositive/ HER2- negative early breast cancer, the cumulative risk of distant recurrence has remained steady for decades.
Olanzapine Significantly Reduces CINV in Patients Receiving MEC
Reimagining Frailty Screenings in Head and Neck Cancer
Screening for Pain and Depression is Not Enough in Cancer Care
Niraparib-Based Triplet Therapy Offers OS Advantage in BRCA1/2+ mCRPC
